Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.
Shuai Tan, Yuxin Li, Yaofang Cao et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed the efficacy and safety of 13 ruxolitinib-based combination regimens for myelofibrosis, using 19 studies involving 1,088 patients. Outcomes included spleen volume reduction of at least 35% and symptom-score reduction of at least 50% at 24 weeks. Among JAK inhibitor-naïve patients, ruxolitinib plus selinexor had the highest reported responses (SVR35: 92%; TSS50: 78%); ruxolitinib plus BMS-986158 had an SVR35 of 90%. In patients previously exposed to a JAK inhibitor, ruxolitinib plus siremadlin had an SVR35 of 45%.
Key findings
- In JAK inhibitor-naïve patients, ruxolitinib plus selinexor achieved SVR35 of 92% and TSS50 of 78%.
- Ruxolitinib plus BMS-986158 had an SVR35 of 90% among JAK inhibitor-naïve patients.
- Among patients with prior JAK inhibitor exposure, ruxolitinib plus siremadlin had an SVR35 of 45%.
Why it matters
Responses to ruxolitinib-based combinations differed according to prior JAK inhibitor exposure, underscoring the importance of treatment history when interpreting efficacy. The findings also identify combinations with reported spleen and symptom responses in clinical studies, while highlighting that results across regimens should not be assumed to apply uniformly to all patients with myelofibrosis.
What to keep in mind
The meta-analysis combined 19 studies of 13 distinct regimens; the abstract does not report comparative randomised evidence or pooled safety results, limiting conclusions about relative efficacy and safety.